-2.88%
Today
Loading 1D prices…
Company profile
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Waltham, MA, United States
Employees
289
Fiscal year end
1231
CIK
1818794
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| RCUSArcus Biosciences Inc. Common Stock | $3.2B | $33M | -1069.70% | -$3.29 | -0.32% | Buy |
| ARQTArcutis Biotherapeutics Inc. Common Stock | $3.3B | $376.1M | -4.29% | -$0.13 | +2.47% | Buy |
| ELVNEnliven Therapeutics Inc. Common Stock | $3.3B | $0.00 | — | -$1.83 | -0.80% | Buy |
| ZLABZai Lab Limited American Depositary Shares | $2.8B | $457.2M | -38.39% | -$0.16 | -1.19% | Buy |
| MRVIMaravai LifeSciences Holdings Inc. Class A Common Stock | $2.8B | $185.7M | -70.42% | -$0.90 | -0.72% | Buy |